Teva Hit With Immediate Appeal After Overcoming US Korlym IP

Corcept Therapeutics Says New Jersey Court Decision ‘Based On Legal, Factual Errors’

 
• By Dean Rudge
  
Generate a summary of this article
Listen to this article
Beta

Teva has gone one better than earlier ANDA settlers Hikma and Sun after winning its long-running legal battle against Corcept Therapeutics over Korlym IP. However, the Israeli firm appears unlikely to launch at risk following an immediate appeal.

Appeal_Gavel
• Source: Shutterstock

Teva may have to face up to a promised appeal from Corcept Therapeutics after the Israeli firm convinced a US district court that its Korlym (mifepristone) generic did not infringe two patents shielding the originator’s branded Cushing’s syndrome treatment, including on the basis that Corcept “failed to introduce credible record evidence that anyone has ever previously infringed” an asserted claim.

Corcept alerted the US District Court for the District of New Jersey on 8 January that it had filed a...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Legal & IP

ADHD

This is regarding ADHD.

GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

 
• By Nabil

In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

MPP Finds Three More Partners On Key Hepatitis C Treatment

 
• By Akriti Seth

The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

 
• By David Wallace

Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C7

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.